Sunday, May 26, 2019
JW’s Third-Generation TPN Products Successfully Land in European Market
JW's Products Approved in U.K., the Netherlands, Belgium
JW’s Third-Generation TPN Products Successfully Land in European Market
  • By Choi Moon-hee
  • April 1, 2019, 12:25
Share articles

JW Life Science has become the first Asian company to export a third-generation total parenteral nutrition (TPN) product to the European market.

JW Life Science is attracting attention by becoming the first Asian company to export a third-generation total parenteral nutrition (TPN) product to the European market.

JW Life Science, a wholly owned subsidiary of JW Holdings, said on March 27 that Baxter, which holds global sales rights to JW Life Science’s three-chamber TPN product Finomel, received a sales license from European countries including the United Kingdom. Tablets, capsules, ampoules and vials produced by Asian pharmaceutical companies have entered the European market before, but this marked the first time that a TPN product from an Asian company made a foray into the European market.

JW developed a three-chamber TPN product in 2013 and signed a licensing-out and export contract with Baxter, the world's number one company in the field of TPN products, in the same year. Baxter has been granted a license to sell the PTN product from the U.K., the Netherlands and Belgium, and is scheduled to launch it in Europe on a full scale in the second quarter of this year. The global third-generation TPN product market is estimated at 1 trillion won and the European third-generation TPN market at 800 billion won.

Finomel is a third-generation TPN with an ideal mixture of Omega-3 and Omega-6, lipid ingredients that expedite patients’ recovery. It is composed of four kinds of lipid ingredients such as purified fish oil (20 percent), refined soybean oil (30 percent), olive oil (25 percent) and MCT (25 percent), glucose and amino acid. The product has the highest Omega 3 content among three-chamber TPN products. Finomel launched as Winuf in Korea in 2013, posted 50.7 billion won in sales in 2018, enjoying its solid number one position in the Korean three-chamber TPN product market.

JW built the world's largest non-polyvinyl chloride (PVC) fluid production line by investing 160 billion won in the Dangjin plant in South Chungcheong Province in 2006. The company explained that the plant meets the international GMP standards from its design stage. The Dangjin plant has introduced a system to automate the whole process and has an annual production capacity to roll out about 130 million units of fluid products.